Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Upgraded by BidaskClub

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports.

A number of other equities research analysts have also recently weighed in on BCYC. Cantor Fitzgerald started coverage on Bicycle Therapeutics in a research note on Monday, October 12th. They set an “overweight” rating and a $30.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, August 6th. Zacks Investment Research cut Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 28th. Oppenheimer reiterated a “buy” rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday, September 22nd. Finally, Canaccord Genuity increased their price target on Bicycle Therapeutics from $23.50 to $25.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.67.

BCYC opened at $18.51 on Friday. The company has a market capitalization of $327.63 million, a PE ratio of -8.90 and a beta of -0.42. The firm has a 50-day simple moving average of $18.98 and a two-hundred day simple moving average of $16.92. Bicycle Therapeutics has a 52 week low of $7.50 and a 52 week high of $21.59.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Wednesday, August 5th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.19). The firm had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $2.11 million. Bicycle Therapeutics had a negative return on equity of 43.74% and a negative net margin of 434.29%. As a group, analysts forecast that Bicycle Therapeutics will post -2.49 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BCYC. FMR LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter valued at approximately $3,277,000. Advisor Group Holdings Inc. grew its holdings in shares of Bicycle Therapeutics by 34,000.0% during the second quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after buying an additional 34,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Bicycle Therapeutics during the first quarter worth $179,000. Morgan Stanley grew its holdings in shares of Bicycle Therapeutics by 32,450.0% during the first quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after buying an additional 3,245 shares in the last quarter. Finally, UBS Group AG purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth $36,000. Institutional investors and hedge funds own 35.54% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Further Reading: Understanding the different types of bonds

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article